Achillion
Pharmaceuticals, Inc. ACHN today provided an update on development of
compounds in its pipeline of therapies for the treatment of chronic hepatitis
C virus, or HCV. Achillion today received a response from the U. S. Food and
Drug Administration, or FDA, on the clinical hold related to sovaprevir,
Achillion's NS3 protease inhibitor. The FDA response indicated that, while
Achillion's submission addressed all issues noted in the FDA's June 29, 2013
letter, the FDA concluded that the removal of the clinical hold is not
warranted.
"While we are disappointed that we were not able to resolve the clinical hold
at this time despite having addressed all the issues, we believe the breadth
of our portfolio allows us to quickly advance other all oral combination
regimens for the treatment of HCV," stated Milind Deshpande, President and
Chief Executive Officer of Achillion. "With our Phase 2 NS5A inhibitor,
ACH-3102, we are in a position to rapidly initiate combination studies with
ACH-2684, our protease inhibitor, with results expected in 2014. Further, we
continue to advance our uridine-analog nucleotide, ACH-3422, with which we
anticipate initiating clinical trials in the first half of 2014."
ACH-2684 has completed all of the necessary preclinical and clinical trials
necessary to support advancement into Phase 2 combination development.
Achillion previously reported robust anti-viral activity with ACH-2684 as
monotherapy including Phase 1b data in both non-cirrhotic and cirrhotic
treatment-naïve HCV genotype (GT) 1 patients. In addition, Achillion will
continue to work to resolve the clinical hold related to sovaprevir.
Phase 2 -007 Trial of Sovaprevir and ACH-3102 with Ribavirin
Achillion also announced interim data from the ongoing -007 Phase 2a clinical
trial evaluating two doses of sovaprevir, either 200 mg or 400 mg once daily,
in combination with 50 mg once daily of ACH-3102 and ribavirin (rbv) twice
daily for 12 weeks in patients with treatment-naïve GT 1a or 1b hepatitis HCV.
The Phase 2 trial is a double-blind, placebo-controlled study evaluating the
safety, tolerability and efficacy of 12 weeks of sovaprevir, ACH-3102 and rbv
in up to 50 treatment-naïve patients with chronic GT 1a or GT 1b HCV. The
first segment enrolled 30 patients who were randomized to receive a
combination of either 200 mg or 400 mg sovaprevir once daily in combination
with a 150 mg loading dose followed by a 50 mg daily dose of ACH-3102, and
twice daily doses of rbv, or matching placebos. The primary endpoints for this
trial include safety, tolerability, and sustained viral response 4 weeks after
the completion of dosing (SVR4). The trial is being conducted at sites in the
United States, Canada, New Zealand and Australia.
All patients achieved a very rapid virologic response (vRVR) with HCV RNA less
than 25 IU/ml by week 2. Potent efficacy was observed against GT 1b HCV with
100% of patients achieving rapid viral response, or RVR, with HCV RNA levels
less than 10 IU/mL at week 4. RVR was achieved in 79% of GT1 patients overall.
To date, the combination of sovaprevir and ACH-3102 with rbv for up to 12
weeks has been well tolerated with no drug-related serious adverse events, no
clinically significant changes in vital signs or electrocardiograms. There
have been no graded increases in liver function tests, including ALT or AST,
for patients receiving active treatment to date. No other laboratory
abnormalities were noted with the exception of decreases in hemoglobin
observed and attributed to ribavirin.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in